ADHD. Disturbance of activity and attention
Conditions
Interventions
Intervention 1: In the first group oral risperidone with the dose of 0.25 mg once daily is started and and increased by 0.25 mg weekly up to 2 mg per day. Intervention 2: In the second group aripipraz
Treatment - Drugs
In the first group oral risperidone with the dose of 0.25 mg once daily is started and and increased by 0.25 mg weekly up to 2 mg per day.
In the second group aripiprazole is started with the dose of 1.25 mg and increased by 1.25 mg weekly up to 10 mg.
Sponsors
Shahrekord University of Medical Sciences
Eligibility
Sex/Gender
All
Age
3 Years to 6 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria:age of 3 to 6 years; affected with disruptive behavior disorders and ADHD based on DSM-IV criteria. Exclusion criteria : mental retardation or other developmental disorders such as autism; chronic physical or neurologic diseases; treatment with other psychotropic medications; development of severe and untolerable medication side effects .
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of ADHD and ODD symptoms. Timepoint: weeks 0, 2 , 4, and 8. Method of measurement: Short and Revised version of Conners Rating Scale parent form.;Rate of improvement. Timepoint: weeks 2, 4 and 8. Method of measurement: CGI-I scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Drug side effects. Timepoint: weeks 2, 4 and 8. Method of measurement: checklist.;Level of prolactine and fasting blood sugar. Timepoint: weeks 0 and 8. Method of measurement: lab data.;Body weight. Timepoint: weeks 0 and 8. Method of measurement: weight measurement. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactParvin Safavi
Shahrekord University of Medical Sciences
Outcome results
None listed